Patents by Inventor Shie-Liang Hsieh

Shie-Liang Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11142795
    Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 12, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Shie-Liang Hsieh, Ya-Lang Huang, Tsung-Yu Tsai
  • Publication number: 20210292413
    Abstract: Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.
    Type: Application
    Filed: September 25, 2018
    Publication date: September 23, 2021
    Applicant: Academia Sinica
    Inventors: Shie-Liang HSIEH, Tsung-Yu TSAI, An-Suei YANG, Chung-Ming YU, Cheng-Yuan PENG
  • Publication number: 20200010898
    Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.
    Type: Application
    Filed: March 15, 2018
    Publication date: January 9, 2020
    Applicant: Academia Sinica
    Inventors: Shie-Liang HSIEH, Ya-Lang HUANG, Tsung-Yu TSAI
  • Patent number: 10172919
    Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: January 8, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Shie-Liang Hsieh, Yung-Chi Chang, Ming-Ting Huang
  • Patent number: 10011646
    Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: July 3, 2018
    Inventors: Shie-Liang Hsieh, Henrich Cheng, Wen-Hung Huang, Chuan-Wen Chiu, Shao-Ji Lin
  • Publication number: 20170360884
    Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.
    Type: Application
    Filed: December 29, 2015
    Publication date: December 21, 2017
    Applicant: Academia Sinica
    Inventors: Shie-Liang HSIEH, Yung-Chi CHANG, Ming-Ting HUANG
  • Publication number: 20170051038
    Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.
    Type: Application
    Filed: August 18, 2016
    Publication date: February 23, 2017
    Applicant: Academia Sinica
    Inventors: Shie-Liang Hsieh, Henrich Cheng, Wen-Hung Huang, Chuan-Wen Chiu, Shao-Ji Lin
  • Publication number: 20150369806
    Abstract: A sensor for detecting molecular interactions between a target and a binding domain by electrochemical impedance spectroscopy. The sensor includes an anodic aluminum oxide barrier layer having a gold-coated array of regularly spaced nano-hemispheres and gold nanoparticles coated with a binding domain attached thereto. Also provided are methods for producing the sensor and for using the sensor to detect the presence of a virus in a sample.
    Type: Application
    Filed: June 17, 2015
    Publication date: December 24, 2015
    Inventors: GOU-JEN WANG, Shie-Liang Hsieh, Yen-Ting Tung
  • Patent number: 8460669
    Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: June 11, 2013
    Assignee: Academia Sinica
    Inventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
  • Publication number: 20120213770
    Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.
    Type: Application
    Filed: May 12, 2011
    Publication date: August 23, 2012
    Applicant: Academia Sinica
    Inventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
  • Patent number: 7998482
    Abstract: The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions. Polysaccharide compositions include those isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: August 16, 2011
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Shie-Liang Hsieh, Tsui-Ling Hsu, Shih-Chin Cheng, Szu-Ting Chen
  • Patent number: 7943134
    Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: May 17, 2011
    Assignee: Academia Sinica
    Inventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
  • Publication number: 20100055096
    Abstract: The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions. Polysaccharide compositions include those isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface.
    Type: Application
    Filed: July 31, 2009
    Publication date: March 4, 2010
    Applicant: Academia Sinica
    Inventors: Chi-Huey Wong, Shie-Liang Hsieh, Tsui-Ling Hsu, Shih-Chin Cheng, Szu-Ting Chen
  • Patent number: 7491397
    Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: February 17, 2009
    Assignee: National Health Research Institutes
    Inventors: Pele Choi Sing Chong, Shie-Liang Hsieh
  • Publication number: 20090022735
    Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
    Type: Application
    Filed: July 28, 2008
    Publication date: January 22, 2009
    Applicant: National Health Research Institutes
    Inventors: Pele Choi Sing Chong, Shie-Liang Hsieh
  • Publication number: 20080292644
    Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.
    Type: Application
    Filed: March 27, 2008
    Publication date: November 27, 2008
    Inventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
  • Publication number: 20080213284
    Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
    Type: Application
    Filed: January 10, 2005
    Publication date: September 4, 2008
    Inventors: Pele Choi Sing Chong, Shie-Liang Hsieh
  • Publication number: 20070072247
    Abstract: The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions. Polysaccharide compositions include those isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface.
    Type: Application
    Filed: August 31, 2006
    Publication date: March 29, 2007
    Applicant: Academia Sinica
    Inventors: Chie-Huey Wong, Shie-Liang Hsieh, Tsui-Ling Hsu, Shih-Chin Cheng, Szu-Ting Chen
  • Publication number: 20040143856
    Abstract: The invention provides the nucleic acid and amino acid sequences of a novel human tumor-associated antigen, placenta derived apoptotic factor (PDAF), and the use of these sequences in the treatment of disorders associated with immune and cell proliferation.
    Type: Application
    Filed: January 15, 2004
    Publication date: July 22, 2004
    Applicant: Anawrahta Biotech Co., Inc., a Taiwan corporation
    Inventors: Wei-Yu Lo, Shie-Liang Hsieh